I usually avoid posting medical content on weekends since most people aren’t thinking about health matters. However, I’m making an exception today. I stumbled upon some studies on bone health, and the first author’s last name is “Bone.” How fitting is that? 😅
It turns out he’s the director of the Michigan Bone and Mineral Clinic! I couldn’t resist sharing this amusing coincidence.
Today, I’m working on an article for the journal Endocrinology about the timing of treatment in osteoporosis. Did you know that osteoporosis and related minimal trauma fractures cost the healthcare system over $2 billion annually? Moreover, one minimal trauma fracture significantly increases the risk of subsequent fractures, yet only 20% of patients start osteoporosis medications after their first fracture. 🤯
A significant portion of my article focuses on the medication denosumab, known by its brand name, Prolia. Prolia is an antibody that targets a protein involved in activating bone-resorbing cells (osteoclasts). It reduces vertebral fractures by 70% and hip fractures by 40%. This biannual injection has become very popular in general practice, with nearly 80% of all osteoporosis medications prescribed in Australia being Prolia.
However, unlike other osteoporosis medications, the benefits of Prolia, such as increased bone-mineral density and fracture protection, are quickly lost once treatment stops. Within 12-18 months, the risk of fractures returns to baseline, and there is some evidence suggesting an increased risk of multiple vertebral fractures. Therefore, if someone starts Prolia, they must adhere strictly to the treatment and transition to another therapy, like bisphosphonates, for 12-18 months if they stop.
Osteoporosis might not seem like an exciting topic, but it should be! Lift heavy weights, consume enough calcium, avoid smoking, and keep your bones healthy. 🦴
Hope you’re having a fun weekend! I’m here with my laptop, wishing my last name was more relevant to my work. 😎